Please login to the form below
cancer patients
This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.
Merck reports positive results for Keytruda combination in malignant pleural mesothelioma
Malignant mesothelioma is a type of cancer that starts in the linings of certain parts of the body, with new cases numbering 30, 000 worldwide in 2020. ... Keytruda’s combination with platinum-based chemotherapy has already become a standard of care in
Latest news
-
AstraZeneca’s Imfinzi shown to improve survival chances in lung cancer patients
AstraZeneca’s (AZ’s) Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy was associated with a significant improvement in event-free survival in certain lung cancer patients, according to new phase 3 ... The late-stage AEGEAN study
-
Roche launches two antibodies to identify mutation status in brain cancer patients
Roche has announced the launch of two new antibodies to identify key mutations in patients diagnosed with brain cancer, allowing clinicians to quickly determine the best treatment path for a specific ... With NICE reporting that the current standard
-
Gilead’s Trodelvy shows promise in phase 2 bladder cancer study
In cohort one, which assessed mUC patients whose cancer had progressed after platinum-based chemotherapy and checkpoint inhibitor therapy (CPI), Trodelvy was associated with a 10.9 months median overall survival, ... The drug is currently approved in
-
Merck reports positive results for Keytruda combination in phase 3 gastric cancer trial
chemotherapy for certain gastric cancer patients. ... Because gastric cancer tends to develop slowly over many years and rarely causes early symptoms, most cases go undetected until an advanced stage, with more than 70% of patients developing
-
Pfizer’s Talzenna combination shows promise in phase 3 prostate cancer study
10-20% of patients develop metastatic prostate cancer within five to seven years of diagnosis. ... Around 10-20% of prostate cancer patients develop mCRPC within five to seven years of diagnosis.
More from news
Approximately 1 fully matching, plus 1,275 partially matching documents found.
Latest Intelligence
-
World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
In colorectal cancer, neoadjuvant I-O resulted in major pathologic responses in 95% of patients, and it led to improved event-free survival in patients with stage III-IV melanoma. ... Data shows that 70% of patients previously treated with other lines
-
Putting the ovation into innovation: trends from ESMO
the ESMO 2020 Congress combination with endocrine therapy and followed this up at ESMO 2022 with further RWE showing stable maintenance of quality of life in patients with advanced breast cancer ... ESMO highlighted how, in an age where cancer medicines
-
Maintaining continuity of care in Ukraine as conflict continues
Eli Lilly’s supply of medicines, including over two million doses of diabetes and cancer products have made their way to hospitals and patients in Ukraine via the company’s humanitarian ... The continued access to oncology treatments has also been an
-
Envisioning a healthier every day, for every woman
certain patients with breast cancer and certain patients with osteoporosis with high risk of fracture.
-
Improving outcomes in oncology – patient-centricity and mental health
By Miranda Stead (pictured) and Holly Ross. More than 50, 000 people are estimated to have missed out on cancer diagnosis during the pandemic, and around half of cancer patients have ... By creating action-led communications, you can support cancer teams
More from intelligence
Approximately 0 fully matching, plus 69 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
promise to create, develop and bring truly differentiated next-generation antibody medicines to cancer patients,” he added.
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness. ... In addition, she brings the perspective of a leading physician who has
-
F-star hires ex-BMS immuno-oncology leader
pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the potential to improve the outcome for cancer patients has never ... He is an active member of the American Society of Clinical
-
New hires at Ferring, Flexion and Immunocore
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
More from appointments
Approximately 0 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
Kate Shaw, Innovative Trials' Founder &CEM, reflects on the exciting news for patients affected by cancer in the UK. ... Kate Shaw, Founder &CEO of Innovative trials, welcomes the news that 29 UK experimental cancer medicine centers (ECMCs) are set to
-
Cholangiocarcinoma - Disease Awareness
Cholangiocarcinoma (CCA) is a rare type of bile duct cancer, and it’s the second most common primary liver cancer in the world. ... Unfortunately, patients with CCA historically have limited treatment options and are often diagnosed at a late or
-
Medscape Medical Affairs are PMEA Finalists in Three Categories
We are committed to advancing the care of cancer patients, and the Transatlantic Exchanges were groundbreaking in many ways. ... There is an enduring need to support clinical researchers in translational medicine to learn from one another and connect and
-
Will the NHS be safe in Liz Truss’s Hands?
Social care is in need and capacity shortages are exacerbating the NHS’s situation by bed blocking hospital patients. ... Expect a growing debate about the poor health outcomes for patients with major diseases such as cancer, cardiovascular disease and
-
Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators
real-world data in the oncology space, where we’ve come to understand the unique and varied ways that cancer presents in individual patients, as well as the potential role that ... Syapse’s oncology platform collects, standardizes, and curates
More from PMHub
Approximately 3 fully matching, plus 78 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- LEO Pharma enters clinical trial partnership with ICON
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- UCB's bimekizumab shows continued improvement in hidradenitis suppurativa patients
- The Considered appoints Bam Zahraie as chief experience officer
- The impact of pharma congresses on HCPs – virtual and in person
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Cello poaches Astellas' Taylor, Con Franklin joins Ketchum, Uptake Strategies expands
- A relentless commitment to neuroscience
- Putting the ovation into innovation: trends from ESMO
- Sanofi to acquire Provention Bio in deal worth $2.9bn
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
